EGFR and non-small cell lung carcinoma: However, it has been suggested that drugs that inhibit HDAC, like MPT0E028, can help overcome this resistance by enhancing cell death when combined with first-line treatments like erlotinib, a frequently used epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor used to treat non-small cell lung cancer.